Covidien — Investor Presentation (May 2013)
15 slides from Covidien's investor presentation, May 3, 2013
Slide 1: Guidance Release May 3, 2013
Confidential GUIDANCE RELEASE May 3, 2013 Exhibit 99.4
Slide 2: Forward-Looking Statements
Confidential Forward-Looking Statements 2 › This presentation contains certain “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to risks, uncertainty
Slide 3: Forward-Looking Statements (continued)
Confidential Forward-Looking Statements (continued) 3 • Our ability to integrate acquisitions of technology, products and businesses • Product liability losses and other litigation liability • The reimbursement practices of a small number of large public and private issuers • Risks associated with c
Slide 4: Spin will create incremental value for Mallinckrodt Specialty Pharmaceuticals
Confidential 4 › Covidien and Mallinckrodt Pharmaceuticals have different business models and product lifecycles › Mallinckrodt has opportunity to unlock potential • Focused R&D, strategic and operational plans • Improved flexibility for infrastructure investment and business development › Separatio
Slide 5: A proud 145-year history of growth
Confidential 5 A proud 145-year history of growth 1867 Formed API1 business in St. Louis, MO 2001 Acquired branded portfolio 2010 Expanded sales force; launched pain products 1920 Launched first contrast media 1966 Launched Radio- pharmaceutical business 1989 Launched Optiray® 2000 Launched Optimark
Slide 6: We make complex products simpler, safer and better for patients
Confidential New We make complex products simpler, safer and better for patients › Specialty Pharmaceuticals and Global Medical Imaging segments › Expertise in controlled substances and pain › Focused, lower-risk R&D strategy › Experienced in formulation › Strong regulatory relationships › Focus on
Slide 7: Mallinckrodt operates in two segments
Confidential Mallinckrodt operates in two segments 7 Specialty Pharmaceuticals Generics/API Brands Global Medical Imaging 1ANDA = Abbreviated New Drug Application 2ADHD = Attention Deficit Hyperactivity Disorder 3GPO = Group Purchasing Organization › Develop products across pain and spasticity › Sel
Slide 8: What makes us different
Confidential What makes us different 8 1 Across the 43 controlled substances in which Mallinckrodt participates 2 Estimated market shares as of Dec. 31, 2012 and reflects Watson’s acquisition of Actavis SOURCE: IMS Health National Sales Perspective (2012) Core Capabilities Mallinckrodt’s Position ›
Slide 9: Brands are our primary growth driver
Confidential 9 Brands are our primary growth driver Why Mallinckrodt? What have we done and where are we going? Q4 2012: Launched Exalgo® 32 mg strength Q4 2012: Acquired Roxicodone® 2010: Expanded sales force and launched pain products Oct 2012: Acquired CNS Therapeutics Post-2013: MNK-795 MNK-155
Slide 10: Generics / API: Strong competitive position supplements our growth
Confidential A P I Gene ric s Generics / API: Strong competitive position supplements our growth and generates cash 10 › #1 or #2 in U.S. for our top 8 generic products / 12th largest in U.S. pharma market by total scripts1,2 › Strong position in U.S. controlled substance generics market with growin
Slide 11: Generic CONCERTA demonstrates core capabilities and contributes to sales growth
Confidential Generic CONCERTA® demonstrates core capabilities and contributes to sales growth 11 18mg 16% 27mg 16% 36mg 43% 54mg 25% Tablet Share by Strength1 5/3/2013 › ANDA approval for Methylphenidate ER2, the generic form of CONCERTA®: Anticipate 180-day exclusivity on three strengths approved •
Slide 12: R&D pipeline represents significant opportunity
Confidential R&D pipeline represents significant opportunity 12 Branded Product Indication Status Market Opportunity (U.S. only) MNK-795 & MNK-155 May be indicated for acute, moderate to severe pain with abuse-deterrent characteristics MNK-795: Phase III complete NDA submission 1H2013 MNK-155: Enter
Slide 13: Mallinckrodt investment summary
Confidential Mallinckrodt investment summary 13 We make complex products simpler, safer and better for patients Achieve sales growth faster than the market in Specialty Pharmaceuticals › Global company focused on pain management and medical imaging diagnostics with 145-year history of pharmaceutical
Slide 14: 2013 Mallinckrodt guidance
Confidential 14 5/3/2013 2013 Mallinckrodt guidance Net Sales Growth 7% to 11% Specialty Pharmaceuticals 21% to 25% Global Medical Imaging -7% to -3% Methylphenidate ER net sales of at least $125M Exalgo net sales of at least $100M Adjusted EBITDA1 as percentage of sales 17% - 21% Fiscal 2013 Effect
Slide 15: 2013 Mallinckrodt guidance: Adjusted EBITDA definition
Confidential 15 5/3/2013 2013 Mallinckrodt guidance Adjusted EBITDA represents earnings before interest, income taxes, depreciation and amortization, adjusted to exclude certain items. These items include, if applicable, discontinued operations; other income, net; separation costs; restructuring cha